Physician profile
Noah Sol Gratch
NPI 1558380816
$5,458.11
in general payments reported to CMS, 2019-2025
23 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $277 · 2021: $603 · 2022: $790 · 2023: $801 · 2024: $1,149 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,828 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,828.24 |
| Education | $191.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $891.73 | 2019-2025 | Tremfya, Stelara, Simponi |
| Leo Pharma INC. | $871.67 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $865.36 | 2019-2025 | |
| Abbvie INC. | $693.44 | 2019-2025 | |
| Genzyme Corporation | $645.27 | 2019-2025 | |
| Pfizer INC. | $280.02 | 2019-2025 | |
| Merz North America, INC. | $183.33 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $158.99 | 2019-2025 | Dupixent |
| Incyte Corporation | $156.95 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $150.16 | 2019-2022 | |
| Celgene Corporation | $118.67 | 2019 | |
| Galderma Laboratories, L.P. | $95.33 | 2019 | |
| Sanofi-Aventis U.S. LLC | $92.00 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.02 | 2019-2020 | |
| Lilly USA, LLC | $43.88 | 2020-2024 | Olumiant |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $24.82 | 2024 | Bimzelx |
| Vyne Pharmaceuticals INC. | $23.61 | 2021 | |
| Dermira, INC. | $22.93 | 2020 | |
| Almirall LLC | $22.81 | 2019 | |
| Horizon Therapeutics Plc | $21.62 | 2019 | |
| Verrica Pharmaceuticals INC. | $19.16 | 2024 | Ycanth |
| Taro Pharmaceuticals USA, INC. | $16.13 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $15.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Gratch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.